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Abstract
Objectives Thrombocytopenia (TP) is a common adverse
effect of linezolid (LZD). However, risk factors for LZD-
associated TP have been reported in Western patients with
relatively heavy body weight. The aim of this study was to
determine the risk factors for LZD-associated TP in Asian
population.
Materials and methods A retrospective cohort study was
conducted among 101 consecutive patients who received
LZD therapy (1,200 mg/day) between July 2003 and
December 2013 at a tertiary referral hospital in Tokyo,
Japan. The patients with obvious other causes for TP were
excluded. The information of target infectious disease,
patients’ age, gender, body weight, body mass index,
baseline serum creatinine (SCr), baseline platelet count,
and treatment duration was collected retrospectively. TP
was defined as C50 % decrease in platelet count from
baseline. Bi- and multi-variate analyses were performed.
Results A total of 101 patients were included (mean age
[SD] 64 [18]; male gender [%], 57 [56]). Median duration
[range] of LZD therapy was 14 days [1–67]. LZD-associ-
ated TP was identified in 42 patients (42 %). For TP,
adjusted odds ratio (OR) [95 % CI] of daily per kg dose
(DPKD) and SCr was 1.14 [1.05–1.26] and 1.51
[1.01–2.50], respectively.
Conclusions Higher DPKD and elevated SCr are signifi-
cantly associated with LZD-associated TP. These findings
suggest that daily dose of LZD should be adjusted using
body weight, as typically done in pediatrics, in adults as
well. Renal function also should be considered for dose
adjustment.
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Introduction
Linezolid (LZD) is an antimicrobial agent with a broad
spectrum of activity against virtually all clinically impor-
tant Gram-positive bacteria, including methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant
enterococci (VRE). An oxazolidinone, its mechanism of
antimicrobial action is primarily bacteriostatic, inhibiting
bacterial toxin production. Both the intravenous and oral
formulations of LZD have nearly 100 % bioavailability
due to its high water solubility and robust tissue penetration
[1, 2]. LZD does not typically require dose adjustment by
body weight (BW) in adults, though dose is determined by
weight in pediatric patients [3, 4]. Thrombocytopenia (TP)
is a common adverse effect in adult patients and the
prevalence has been reported about 15–50 % with different
definitions [5–9]. Prolonged treatment duration [9, 10],
renal insufficiencies [1, 2, 9, 11–13], chronic liver disease
[11], malignancy [14], previous vancomycin use [15],
baseline platelet count [16], and lower BW [7, 8, 17] have
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been reported as possible risk factors for LZD-associated
TP. However, most of previous studies have been con-
ducted in Western patients with relatively heavy BW. The
aim of this study was to identify the independent risk
factors for LZD-associated TP in Asian population.
Materials and methods
A retrospective cohort study was conducted among 101
consecutive patients who received LZD therapy (1,200 mg/
day) for the first time between July 2003 and December
2013 at a tertiary referral hospital in Tokyo, Japan. Within
the study period, 230 adults (age C 20) have received LZD
therapy. Those who had previously received LZD therapy
(n = 85), with an acute DIC score C4 points (n = 24) [18],
a hematological disorder (n = 15), or a definite diagnosis of
prior drug-associated TP (n = 5) were excluded.
All patients received a total daily dose of 1,200 mg
(600 mg, q12hr) regardless of BW. The information of
target infectious disease, patients’ age, gender, BW, body
mass index (BMI), baseline serum creatinine (SCr), base-
line platelet count, and treatment duration was collected
retrospectively. TP was defined as C50 % platelet count
decrease from baseline [19]. Baseline platelet count was
defined as platelet count at initiation of LZD therapy. If
there was no platelet data on the first day of LZD therapy,
the closest previous platelet data prior to LZD therapy was
used as baseline platelet count. Laboratory data were
obtained between baseline and 14 days after discontinua-
tion of LZD. Platelets were measured 2–3 times per week.
Bi- and multi-variate analyses were performed.
Statistical analysis
Fisher’s exact test was used for comparison of proportions,
while Student’s t test was used for continuous variables.
Bivariate and multivariate logistic regression analyses were
subsequently conducted. Variables with P value less than
0.2 in bivariate analyses were principally added in multi-
variate analysis. Clinically relevant variables which have
been previously reported to be associated with TP were
also included in multivariate analysis.
All analyses including confidence intervals were two-
sided, and P \ 0.05 was considered statistically significant.
All statistical analyses were performed using JMP ver-
sion 10 statistical software (SAS Institute, Cary, NC).
Results
A total of 101 patients were included in our analysis.
Baseline characteristics are listed in Table 1. The patients’
mean age was 64 years, 56 % of them were male. Mean
body weight was 57.3 kg. Patient with BMI less than 20
was 33 %. Mean (SD) daily per kg dose (DPKD) (mg/kg/
day) of LZD was 21.39 (5.51). Its range (mg/kg/day) was
[7.95–35.29]. Median duration [range] of LZD therapy was
14 days [1–67].
LZD was mainly administrated for surgical infection,
cellulitis, urinary tract infection, artificial device infection
and osteomyelitis (Table 1). The main indication of LZD
was definite or suspected MRSA infection. For these
patients, LZD was chosen for following reasons: (1) side
effects of other anti-MRSA antibiotics (49 %); (2) antibi-
otics failure (31 %); and (3) outpatient therapy (29 %). In
24 % of the total cases (MRSA 16.8 %, possible MRSA
Table 1 Patients’ characteristics
Characteristics and underlying medical conditions Value
Number of patients 101
Age (years)a, mean (SD) 64 (18)
Male, n (%) 57 (56)
BW (kg)a, mean (SD) 57.3 (17.3)
BMI (kg/m2)a, mean (SD) 23.02 (6.6)
BMI less than 20, n (%) 33 (33)
Treatment duration (days), median (range) 14 (1–67)
DPKD (1,200/BW (mg/kg)), mean (SD) 21.39 (5.51)
Serum creatinine (mg/dL)a, median (range) 0.87 (0.24–7.47)
eGFR (mL/min/1.73 m2)a, median (range) 61.58 (6.64–325.43)
CCr (mL/min)a, median (range) 61.29 (9.76–557.07)
Baseline Plt (9103/lL)a, mean (SD) 266 (133)
Diagnosis
Surgical site infection, n (%) 21 (20.8)
Cellulitis, n (%) 15 (14.9)
Urinary tract infection, n (%) 12 (11.9)
Artificial device infectionb, n (%) 10 (9.9)
Osteomyelitis, n (%) 7 (6.9)
Pneumonia, n (%) 5 (5.0)
Pyothorax, n (%) 4 (4.0)
Infective endocarditis, n (%) 3 (3.0)
Epidural abscess, n (%) 2 (2.0)
Pyogenic arthritis, n (%) 2 (2.0)
Toxic shock syndrome, n (%) 2 (2.0)
Perforation of gastrointestinal tract, n (%) 2 (2.0)
Others, n (%) 14 (13.9)
Baseline disease
Diabetes mellitus, n (%) 34 (33.7)
Hypertension, n (%) 58 (57.4)
Hyperlipidemia, n (%) 38 (37.6)
BW body weight, BMI body mass index, DPKD daily per kg dose,
eGFR estimated glomerular filtration rate, CCr creatinine clearance
a Before linezolid administration
b Eight cases of intravascular device, one case of urine stent, one case
of artificial breast (post expander-implant breast reconstruction)
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6.9 %), LZD was administered due to the failure of other
antimicrobial therapy. Patients with VRE infection were
rare (3.9 %).
LZD-associated TP was found in 42 of 101 patients
(42 %). The mean age, and DPKD were significantly
higher in thrombocytopenic patients than in non-thrombo-
cytopenic patients. The median creatinine clearance (CCr)
was significantly lower in thrombocytopenic patients
(Table 2). Platelet decreases of C50 % and final platelet
counts of\150 9 103/lL were identified in 31 % (31/101)
of patients. TP with a final count of \100 9 103/lL was
seen in 26 % (26/101) of patients. Age, DPKD, BW and
CCr were significantly associated with LZD-induced TP in
bivariate analyses. For TP, adjusted odds ratio (OR) [95 %
CI] of DPKD and SCr was 1.14 [1.05–1.26] and 1.51
[1.01–2.50], respectively (Table 3).
When patients were categorized into four groups using
three cut-off values (45, 55, 75 kg) of BW, the prevalence of
TP in each group was 72 % (13/18), 48 % (12/25), 34 % (13/
38), and 17 % (4/23) in the patients with DPKD C 27
(BW B 45 kg), 22 B DPKD \ 27 (45 kg\ BW B 55 kg),
17 B DPKD \ 22 (55 kg\ BW B 70 kg), DPKD \ 17
(BW[ 70 kg), respectively (Fig. 1).
Discussion
Our study suggests that LZD-associated TP is associated
with high DPKD and renal insufficiency.
The mechanism of LZD-associated TP is thought to be
due to reversible myelosuppression [20]. Nonetheless,
several case reports suggested that patients with LZD-
associated TP retain adequate numbers of megakaryocytes
in their bone marrow [21, 22]. Immune-mediated platelet
destruction has been suggested based on a decreased rate of
TP following immunoglobulin therapy [21]. Given multi-
ple plausible mechanisms, the pathophysiology of LZD-
associated TP remains controversial.
Table 2 Bivariate analyses
Thrombocytopenic
patients (n = 42)
Non-
thrombocytopenic




67.83 (15.59) 61.76 (19.05) 0.041**





23.47 (5.10) 19.91 (5.35) 0.0011**
BW (kg),
mean (SD)
53.64 (12.12) 64.75 (18.94) 0.0012**
SCr (mg/dL),
median (range)
















14 (3–67) 14 (1–63) 0.36*
* Kruskal–Wallis test
** Student’s t test
a CCr (mL/min) = (140 - age) 9 weight/72 SCr, female times 0.85.
Formula of Cockcroft
SD standard deviation, DPKD daily per kg dose, BW body weight,
SCr serum creatinine, CCr creatinine clearance
Table 3 Bi-and multi-variate logistic regression



































OR odds ratio, CI confidence interval, SCr serum creatinine, DPKD
daily per kg dose
Fig. 1 The prevalence of linezolid-associated thrombocytopenia
stratified by daily per kg dose (DPKD) (mg/kg/day). The prevalence
of thrombocytopenia is linearly associated with DPKD of linezolid. In
22 B DPKD \ 27, the prevalence of TP was 48 %. Its prevalence
increased to 72 % in DPKD C 27
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Niwa et al. [17], though using a different definition of TP
at C25 % platelet decrease and final platelet count of
\100 9 103/lL, reported that DPKD C22 mg/kg and a
baseline platelet count\200 9 103/lL were significant risk
factors for LZD-associated TP. Their study introduced the
possibility of dose modification with linezolid [23]. In our
study, we defined TP as a platelet decrease of C50 % as this
level, while platelet count still in the normal range, may
herald severe clinical problems, and requires active follow-
up. Vanderschueren et al. [19] reported that drop in platelet
count to \50 % of admission was associated with higher
death rates in the ICU patients. Under this definition, LZD-
associated TP was found in 42 of 101 patients (42 %)
(Table 2). Considering the DPKD of 22 mg/kg that Niwa
reported, when the patients were divided into four groups
[DPKD C 27 (*BW B 45 kg), 22 B DPKD \ 27 (*45 kg
\BW B 55 kg), 17 B DPKD \ 22 (*55 kg \ BW B
70 kg), DPKD \ 17 (*BW [ 70 kg)], the prevalence of
TP increased to 72 % in the group of DPKD C 27 (* BW
B 45 kg) (Fig. 1) is an impressive result.
A recent randomized controlled study [5] reported that
the incidence of LZD-associated TP (platelet count,
\150 9 103/lL if normal at baseline or 50 % decrease if
low at baseline) was 16.3 %, the mean BW (SD) of subjects
being 78.1 kg (23.3). This prevalence rate is similar to the
prevalence of TP in the DPKD \17 category in our study.
According to LZD phase 3 trials in Japan, adverse
events developed in 64.3 % (9/14) in those subjects with
BW\ 40 kg, and 53 % (44/83) in those with BW C 40 kg
[24]. These findings were similar to our results, in which
the prevalence of TP was 70 % in patient B45 kg.
In pediatric patients, especially those with lower BW,
the daily dose of LZD requires adjustment by BW. We
think that it is similarly reasonable to suggest weight-based
dosing for LZD even in relatively lower weight adults.
Elevated SCr was also independently associated with
LZD-associated TP. A previous phase 3 trial [24] showed
that the pharmacokinetics of LZD is not influenced by age,
hepatic function, or renal function (CCr [ 30). Moreover,
in serial oral administration tests for patients with end-
stage renal disease, plasma LZD concentrations were not
influenced by renal function [24]. LZD is metabolized by
non-enzymatic chemical oxidation and 30–40 % is excre-
ted unchanged in the urine [25–30]. It is thought that LZD
is not metabolized by cytochrome P450, as it shows none
of the induction or inhibitory effects associated with vari-
ous human cytochrome P450 enzyme activities. However,
after coming to market, the association between LZD-
associated adverse events (including TP) and renal insuf-
ficiency [1, 2, 12], chronic liver disease [12], prolonged
administration [11], malignancy [15] and previous vanco-
mycin use [16] have been reported. In particular, renal
insufficiency has been reported frequently as a risk factor
of LZD-associated TP in recent studies [1, 2, 31, 32]. Our
results corroborate these findings. Prolonged treatment
duration (TD) of LZD was reported as the main risk factor
of LZD-associated TP [16, 33]. However, our study
showed no association between TD and TP.
Area under the blood concentration–time curve (AUC)
value of LZD has been reported to be higher in subject
older than 80 years and BW less than 40 [24]. The mean
AUC value (SD) of these subjects was 811.3 (280.7) lg h/mL.
This value is 3.7 times of the subjects with age \80 and
BW C 40 [217.6 (129.9) lg h/mL] [24]. On the safety
of high-exposure examination, adverse event prevalence
was found in 7 of 11 subject (63.6 %) in the high-exposure
subjects (AUC C 800 lg h/mL), 41 of 80 (51.3 %) in the
non-high-exposure subjects (AUC \ 800 lg h/mL). Nukui
et al. [32] reported that high plasma LZD trough concen-
tration is a risk factor for TP. Dong et al. [7] reported the
minimum trough level (Cmin) of linezolid was significantly
higher in patients with TP than in those without TP
(8.81 mg/L [1.98–37.54] vs. 2.88 mg/L [0.35–8.78],
P \ 0.0001). Matsumoto et al. [34] reported that the trough
concentration of LZD [mg/L] was 14.4–35.6 versus (vs.)
6.9–7.2 and the area under the plasma linezolid concen-
tration–time curve for 24 h (AUC24 h) [mg h/L] was
513.1–994.6 vs. 294.3–323.6 in the thrombocytopenic vs.
non-thrombocytopenic patients. In addition, several recent
Japanese studies have discussed the relationship between
LZD blood concentration and TP [35–37]. As mentioned
above, the fact that AUC value of LZD is relatively high in
low BW subjects has been previously demonstrated in the
phase 3 clinical trials in Japan [24]. Our results strongly
suggest that high DPKD and elevated SCr are indepen-
dently associated with LZD-associated TP. Therefore, we
assume that higher DPKD and renal dysfunction are related
to TP via higher serum LZD concentrations.
This is the first study suggesting a DPKD-dependent
linear association between LZD and TP by categorizing
DPKD into four groups. As this is a single center study
among Japanese, our findings warrant external validation.
In conclusion, both higher DPKD and elevated SCr are
significant risk factors for LZD-associated TP. As is done
in pediatric patients, the daily dose of LZD should be
adjusted by BW in adults as well. Renal function also
should be considered for dose adjustment.
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